Hostname: page-component-594f858ff7-hf9kg Total loading time: 0 Render date: 2023-06-07T21:37:00.229Z Has data issue: false Feature Flags: { "corePageComponentGetUserInfoFromSharedSession": true, "coreDisableEcommerce": false, "corePageComponentUseShareaholicInsteadOfAddThis": true, "coreDisableSocialShare": false, "useRatesEcommerce": true } hasContentIssue false

Decreased Hippocampal Expression of a Glutamate Receptor Gene in Schizophrenia

Published online by Cambridge University Press:  02 January 2018

John Collinge
Prion Disease Group, Department of Biochemistry and Molecular Genetics, St Mary's Hospital Medical School, Norfolk Place, London W2 1PG
David Curtis
Molecular Psychiatry Laboratory, Academic Department of Psychiatry, University College and Middlesex School of Medicine, Riding House Street, London W1P 7PN


‘A striking and specific loss of the messenger RNA that encodes a non-N-methyl D-aspartate (non-NMDA) glutamate receptor was found in hippocampal tissue obtained at necropsy from 6 patients with schizophrenia, when compared to specimens from 8 controls without neurological or psychiatric signs or symptoms. These findings support suggestions of aberrant glutamatergic function in schizophrenia. Evidence that gene expression may be abnormal in schizophrenia, with decreased production of an excitatory neurotransmitter receptor, may have therapeutic as well as pathogenetic implications.’

The Current Literature
Copyright © 1991 The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)


Carlsson, M. & Carlsson, A. (1990) Interactions between glutamatergic and monoaminergic systems within the basal ganglia – implications for schizophrenia and Parkinson's disease. Trends in Neuroscience, 13, 272276.CrossRefGoogle ScholarPubMed
De La Concha, A., McKie, J., Hodgkinson, S., et al (1991) Stereospecific effect of flupenthixol on neuroreceptor gene expression. Molecular Brain Research (in press).Google Scholar
Deakin, J. F., Slater, P., Simpson, M. D., et al (1989) Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia. Journal of Neurochemistry, 52, 17811786.CrossRefGoogle Scholar
Freed, W. J. (1988) The therapeutic latency of neuroleptic drugs and nonspecific postjunctional supersensitivity. Schizophrenia Bulletin, 14, 269277.CrossRefGoogle ScholarPubMed
Harrison, P. J., McLaughlin, D. & Kerwin, R. W. (1991) Decreased hippocampal expression of a glutamate receptor gene in schizophrenia. Lancet, 337, 450452.CrossRefGoogle Scholar
Kerwin, R. W., Patel, S. & Meldrum, B. S. (1990) Quantitative autoradiographic analysis of glutamate binding sites in the hippocampal formation in normal and schizophrenic brain post mortem. Neuroscience, 39, 2532.CrossRefGoogle ScholarPubMed
Kim, J. S., Claus, D. & Kornhuber, H. H. (1983) Cerebral glutamate, neuroleptic drugs and schizophrenia: increase of cerebrospinal fluid glutamate levels and decrease of striate body glutamate levels following sulpiride treatment in rats. European Neurology, 22, 367370.CrossRefGoogle ScholarPubMed
Toru, M., Watanabe, S., Shibuya, H., et al (1988) Neurotransmitters, receptors and neuropeptides in post-mortem brains of chronic schizophrenic patients. Acta Psychiatrica Scandinavica, 78, 121137.CrossRefGoogle ScholarPubMed
Van Tol, H. H. M., Riva, M., Civelli, O., et al (1990) Lack of effect of chronic dopamine blockade on D2 receptor mRNA level. Neuroscience Letters, 111, 303308.CrossRefGoogle Scholar
Submit a response


No eLetters have been published for this article.